CMTTdb

An integrated database for cancer molecular targeted thearpies

Entry Detail


General information
Database:DB00683
Objective:The purpose of this study was to evaluate the safety and efficacy of the combination of sorafenib and bevacizumab in patients with advanced neuroendocrine tumours.
Authors:Castellano D, et al
Title:A doseescalatingphase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
Journal:Eur J Cancer.
Year:2013
PMID:24012098
Trial Design
Clinical Trial Id:NA
Agent:Sorafenib and bevacizumab
Target:NA
Cancer Type:neuroendocrine tumour
Cancer Subtype:advanced neuroendocrine tumours
Therapy Type:com
Therapeutic Combination Type:1
Therapeutic Combination Content:sorafenib+bevacizumab
Study Type:Openlabel, uncontrolled, multicenter, phase II clinical trial
Key Patients Feature:Eligible patients had histologically confirmed measurable advanced NETs (carcinoid tumour, includingbronchial location; islet cell carcinoma; or other moderately or welldifferentiated tumours). Eligibility criteriaincluded age P18 years; Eastern Cooperative OncologyGroup (ECOG) performance status of 0-2; adequate haematological, liver and renal function (defined asabsolute neutrophil count P 1.5 109 /L; total platelets P 100 109 /L; total bilirubin 62 upper limit ofnormal (ULN), AST and ALN 63 ULN (or <5 ULN in hepatic metastasis); total creatinine level61.5 ULN) and a life expectancy of at least 24 weeks.Measurable disease was required for all patients.
Biomarker:NA
Biomark Analysis:NA
Control Group Info:single arm
Treatment Info:sorafenib 200mg bid (days 15 of each week) and bevacizumab 5mg/kg once every 2 weeks (day 1, week 1). Tumour response was performed according to RECIST (v1.0) every 2 months during the treatment period. Adverse events were graded according to CTCAE (v3.0).
Primary End Point:progression free survival rate (PFSR) after 6 months of treatment with the combination of sorafenib and bevacizumab.
Secondary End Point:overall progression free survival(PFS), time to progression (TTP), overall survival (OS) and safety and tolerability,disease control rate and objective response rate
Patients Number:44
Trial Results
DLT_MTD:NA
Objective Response Rate:NA
Disease Control Rate:NA
Median Time to Progression:14.5 months (95%CI: 9.7not achieved) in patients with the combination therapy.
Median PFS A vs. C:in patients with the combination therapy was 12.4 months (95% confidence interval (CI): 9.4-16.2). Median PFS by type of tumour was 11.4 (95%CI: 8.9-16.2) months forcarcinoid tumours and was not reached for pancreatic tumours.
Median OS A vs. C:NA
Adverse Event(agent arm):The most common AEs were asthenia, hand-foot syndrome (HFS), mucositis, diarrhoea and hypertension. Less than 10% of patients had haematologic toxicities (two patients leukopaenia and one patient anaemia).
Conclusions:Sorafenib and bevacizumab combination showed clinical benefit but unfavourable safety results compared with drugs in monotherapy. Further development of this combination is not warranted and a sequential approach is recommended instead.